Lack of genetic and epigenetic changes in meningiomas without NF2 loss

Journal of Pathology

Volumn 208, Issue 4, 2006, Pages 564-573

  van Tilborg, Angela A G ^a   Morolli, Bruno ^b   Giphart Gassler, Micheline ^b   de Vries, Annie ^a   van Geenen, Daniëlle A N ^a   Lurkin, Irene ^a   Kros, Johan M ^a   Zwarthoff, Ellen C ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allelotyping; Meningioma; Methylation

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; DNA; ERYTHROCYTE BAND 4.1 PROTEIN; EZRIN; GLUTATHIONE TRANSFERASE P1; MOESIN; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P73; RADIXIN; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR BETA; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME ARM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE FREQUENCY; GENE INACTIVATION; GENE LOCATION; GENE SILENCING; GENETIC POLYMORPHISM; GENETIC SCREENING; HETEROZYGOSITY LOSS; HUMAN; KARYOTYPING; MALE; MENINGIOMA; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SKULL BASE; TELOMERE; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; X CHROMOSOME;

ADULT; AGED; ALLELES; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MENINGIOMA; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM PROTEINS; NEUROFIBROMIN 2; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SKULL BASE NEOPLASMS;

EID: 33644666031     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1909     Document Type: Article

References (45)

1. Dumanski JP, Carlbom E, Collins VP, Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci U S A 1987;84(24):9275-9.
2. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci USA 1987;84(15):5419-23.
3. Papi L, De Vitis LR, Vitelli F, Ammannati F, Mennonna P, Montali E, et al. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 1995;95(3):347-51.
4. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, et al. Type of mutation in the neurotibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59(2):331-42.
5. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995;146(4):827-32.
6. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, et al. NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 2001;194(3):367-72.
7. Lekanne Deprez RH, Riegman PH, van Drunen E, Warringa UL, Groen NA, Stefanko SZ, et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54(2):224-35.
8. Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, et al. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 200-;94(1):111-7.
9. Carlson KM, Bruder C, Nordenskjold M, Dumanski JP. 1p and 3p deletions in meningiomas without detectable aberrations of chromosome 22 identified by comparative genomic hybridization. Genes Chromosomes Cancer 1997;20(4):419-24.
10. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88(12):2887.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16(3):1215.
12. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van Der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000;9(20):297 3-80.
13. van Tilborg AA, De Vries A, De Bont M, Groenfeld LE, Zwarthoff EC. The random development of LOH on chromosome 9q in superficial bladder cancers. J Pathol 2002;198(3): 352-358.
14. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial pre-disposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58(22):5248-57.
15. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72(5):791-800.
16. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002;62(9):2447-54.
17. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3(6):415-28.
18. de Nooij-van Dalen AG, van Buuren-van Seggelen VH, Lohman PH, Giphart-Gassler M. Chromosome loss with concomitant duplication and recombination both contribute most to loss of heterozygosity in vitro. Genes Chrom Cancer 1998;21(1):30-8.
19. Hagstrom SA, Dryja TP. Mitotic recombination map of l3cen-l3q14 derived from an investigation of loss of heterozygosity in retinoblastomas. Proc Natl Acad Sci USA 1999;96(6):2952-7.
20. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 1999;59(23):5995-8.
21. Ichii S, Takeda S, Horii A, Nakatsuru S, Miyoshi Y, Emi M, et al. Detailed analysis of genetic alterations in colorectal tumors from patients with and without familial adenomatous polyposis (FAP). Oncogene 1993;8(9):2399-405.
22. Bostrom J, Muhlbauer A, Reifenberger G. Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol (Berl) 1997;94(5):479-85.
23. Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma. pathogenesis. Neurobiol Dis 2003;13(3):191-202.
24. Diaz de Stahl T, Hansson CM, Bustos Cd, Mantripragada. KK, Piotrowski A, Benetkiewicz M, et al. High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. Human Genetics 2005;118():35-44.
25. Lamszus K, Vahldiek F, Mautner VF, Schichor C, Tonn J, Stavrou D, et al. Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 2000;59(6):504-12.
26. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M. Allelic losses at lp, 9q, l0q, l4q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999;110(2): 103-10.
27. Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent protein kinase phosphorylates Merlin at serine 518 independently of P21-activated kinase and promotes Merlin-Ezrin heterodimerization. J Biol Chem 2004;279(18):18559-66.
28. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10(5):201-4.
29. Curto M, McClatchey AI. Ezrin...a metastatic detERMinant? Cancer Cell 2004;5(2):113-4.
30. Simon M, Kokkino AJ, Warnick RE, Tew JM, Jr., von Deimling A, Menon AG. Role of genomic instability in meningioma progression. Genes Chromosomes Cancer 1996;16(4):265-9.
31. Pykett MJ, Murphy M, Harnish PR, George DL. Identification of a microsatellite instability phenotype in meningiomas. Cancer Res 994;54(24):6340-3.
32. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, et al. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 2005;42(3):314-9.
33. Kirsch M, Zhu JJ, Black PM. Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas. Genes Chromosomes Cancer 1997;20(1):53-9.
34. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118(3):277-9.
35. Schwechheimer K, Zhou L, Birchmeier W. E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas. Virchows Arch 1998;432(2):163-7.
36. Figarella-Branger D, Pellissier JF, Bouillot P, Bianco N, Mayan M, Grisoli F, et al. Expression of neural cell-adhesion molecule isoforms and epithelial cadherin adhesion molecules in 47 human meningiomas: correlation with clinical and morphological data. Mod Pathol 1994;7(7):752-61.
37. Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, et al. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med 1998;4(8):915-22.
38. Kino T, Takeshima. H, Nakao M, Nishi T, Yamamoto K, Kimura T, et al. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 2001;6(5):441-54.
39. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61(1):249-55.
40. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000;6(9):3516-21.
41. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93(18):9821-6.
42. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000;60(19):5329-33.
43. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001;7(7):1998-2004.
44. Liu M, Taketani T, Li R, Takita J, Taki T, Yang HW, et al. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk Res 2001;25(6):441-7.
45. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000;60(5):1211-6.